Compare Merck & Co., Inc. (MRK) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nerdwallet Inc — how do they compare? Merck & Co., Inc. trades at $148.16 (market cap $363.98B), while Nerdwallet Inc trades at $9.41 (market cap $598.32M). The key difference: Merck & Co., Inc. is far larger — about 608.3× Nerdwallet Inc's market cap, and Merck & Co., Inc. pays a 2.3% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| MRK | NRDS | |
|---|---|---|
Market Cap | $363.98B | $598.32M |
Sector | Health | Financials |
52-Week High | $156.43 | $15.93 |
52-Week Low | $77.60 | $7.58 |
Enterprise Value | $410.75B | $512.62M |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
NerdWallet (NRDS) trades at $9.56, down 3.24% today, amid a bearish technical signal. The stock shows strong fundamentals with a low P/E of 10.4 and P/S of 0.78, alongside robust revenue growth from $539M in 2022 to $837M in 2025. Recent Q2 2026 earnings missed estimates at $0.07 per share, but Q1 and Q4 2025 beat expectations. Operating cash flow improved to $132M in 2025, though net cash flow turned negative in 2026 projections.
Outlook is mixed: valuation metrics suggest upside potential, with a 66.7% analyst buy rating and a 27.9% price target upside per Zacks (August 10, 2026). However, technical weakness and Q2 earnings miss pose near-term risks. Key catalysts include continued revenue growth and margin expansion, but reliance on organic search traffic remains a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
